Gilead Sciences, Inc., through its Kite Pharma subsidiary, has taken the lead in the CD19-directed CAR-T cell therapy market with Yescarta (axicabtagene ciloleucel), a position that appears to be reinforced by new, longer-term data in large B-cell lymphoma (LBCL) that were presented at the American Society of Clinical Oncology meeting.
Kite reported results from the Phase III ZUMA-7 clinical trial of Yescarta at ASCO on 5 June. The study tested...








